- Joined
- Feb 8, 2004
- Messages
- 8,026
- Reaction score
- 4,159
1) Patient doesn't want family member in the meeting, but family member is paying for the visits and won't pay for visits unless that family member is included in the meetings.
2) Patient needs a dental consult because of a severe dental problem. Most hospitals don't have dentists, but patient is involuntarily committed in the psych unit and too dangerous to discharge. IM pretty much tells you to eff off cause it's dental and not something they treat when you ask them to consult.
3) Patient has severe ADHD. Patient is also in their 70s, not in the best of health making stimulants have some risk (Hypertension, patient is a smoker). Non-stimulants were tried without benefit. Only med that helps is a stimulant. Do you cut the stimulant off?
4) Medication is on a tradename med, and it works great. Several generics were tried and failed. Medication goes generic so now insurance won't pay for the tradename medication cause it went generic. Problem is the medication JUST WENT GENERIC and the generics aren't expected to hit the shelves for several months. (This happened with Latuda in January and will happen with Vyvanse around August).
2) Patient needs a dental consult because of a severe dental problem. Most hospitals don't have dentists, but patient is involuntarily committed in the psych unit and too dangerous to discharge. IM pretty much tells you to eff off cause it's dental and not something they treat when you ask them to consult.
3) Patient has severe ADHD. Patient is also in their 70s, not in the best of health making stimulants have some risk (Hypertension, patient is a smoker). Non-stimulants were tried without benefit. Only med that helps is a stimulant. Do you cut the stimulant off?
4) Medication is on a tradename med, and it works great. Several generics were tried and failed. Medication goes generic so now insurance won't pay for the tradename medication cause it went generic. Problem is the medication JUST WENT GENERIC and the generics aren't expected to hit the shelves for several months. (This happened with Latuda in January and will happen with Vyvanse around August).